Corcept Therapeutics is trading 4.3% up at $95.53, rebounding as investors focus on the company's de-risked oncology franchise and clarity regarding historical legal challenges.
- Recent coverage highlights the March 2026 FDA approval of Lifyorli for platinum-resistant ovarian cancer and ambitious revenue targets for 2026.
- Market sentiment is improving as securities class actions related to the prior relacorilant CRL are now well-defined and considered largely priced in.
- The stock is showing significant resilience and renewed demand despite broader weakness across the biotechnology sector.